Endocannabinoids anandamide and 2-arachidonoylglycerol are substrates for human CYP2J2 epoxygenase

Journal of Pharmacology and Experimental Therapeutics

Volumn 351, Issue 3, 2014, Pages 616-627

  McDougle, Daniel R ^a   Kambalyal, Amogh ^b   Meling, Daryl D ^b   Das, Aditi ^a,b,c  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c University of Illinois at Urbana Champaign   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; ARACHIDONIC ACID; CARBOXYLIC ACID; CYTOCHROME P450 2J2; EPOXIDE; EPOXYICOSATRIENOIC ACID; 2-ARACHIDONYLGLYCEROL; ACYLGLYCEROL; AMIDE; ARACHIDONATE EPOXYGENASE; ARACHIDONIC ACID DERIVATIVE; CYTOCHROME P450; ENDOCANNABINOID; PROTEIN BINDING;

ANIMAL CELL; ARTICLE; CHEMICAL MODIFICATION; CHEMICAL REACTION; ENZYME ACTIVE SITE; ENZYME METABOLISM; ENZYME SUBSTRATE; FATTY ACID OXIDATION; FEMALE; HEART MUSCLE; MALE; MICROSOME; NONHUMAN; PROTEIN LIPID INTERACTION; ANIMAL; BOVINE; CHEMISTRY; ENZYME SPECIFICITY; HUMAN; METABOLISM; PHYSIOLOGY; PIG; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; RAT;

ANIMALS; ARACHIDONIC ACIDS; CATTLE; CYTOCHROME P-450 ENZYME SYSTEM; ENDOCANNABINOIDS; FEMALE; GLYCERIDES; HUMANS; MALE; POLYUNSATURATED ALKAMIDES; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RATS; SUBSTRATE SPECIFICITY; SWINE;

EID: 84908425369     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.216598     Document Type: Article

References (44)

1. Alghasham A, Ali A, Ismail H, Dowaidar M, and Settin AA (2012) CYP2J2 -50 G/T and ADRB2 G46A gene polymorphisms in Saudi subjects with hypertension. Genet Test Mol Biomarkers 16:1027-1031.
2. Baudry J, Li W, Pan L, Berenbaum MR, and Schuler MA (2003) Molecular docking of substrates and inhibitors in the catalytic site of CYP6B1, an insect cytochrome p450 monooxygenase. Protein Eng 16:577-587.
3. Baudry J, Rupasinghe S, and Schuler MA (2006) Class-dependent sequence alignment strategy improves the structural and functional modeling of P450s. Protein Eng Des Sel 19:345-353.
4. Bayburt TH and Sligar SG (2010) Membrane protein assembly into nanodiscs. FEBS Lett 584:1721-1727.
5. Bidwai AK, Meyen C, Kilheeney H, Wroblewski D, Vitello LB, and Erman JE (2013) Apolar distal pocket mutants of yeast cytochrome c peroxidase: hydrogen peroxide reactivity and cyanide binding of the TriAla, TriVal, and TriLeu variants. Biochim Biophys Acta 1834:137-148.
6. Blankman JL, Simon GM, and Cravatt BF (2007) A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 14:1347-1356.
7. Capdevila JH, Dishman E, Karara A, and Falck JR (1991) Cytochrome P450 arachidonic acid epoxygenase: stereochemical characterization of epoxyeicosatrienoic acids. Methods Enzymol 206:441-453.
8. Chen JK, Chen J, Imig JD, Wei S, Hachey DL, Guthi JS, Falck JR, Capdevila JH, and Harris RC (2008) Identification of novel endogenous cytochrome p450 arachidonate metabolites with high affinity for cannabinoid receptors. J Biol Chem 283:24514-24524.
9. Cravatt BF and Lichtman AH (2003) Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr Opin Chem Biol 7:469-475.
10. Das A, Varma SS, Mularczyk C, and Meling DD (2014) Functional investigations of thromboxane synthase (CYP5A1) in lipid bilayers of nanodiscs. ChemBioChem 15:892-899.
11. Delozier TC, Kissling GE, Coulter SJ, Dai D, Foley JF, Bradbury JA, Murphy E, Steenbergen C, Zeldin DC, and Goldstein JA (2007) Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Metab Dispos 35:682-688.
12. Denisov IG, Grinkova YV, McLean MA, and Sligar SG (2007) The one-electron autoxidation of human cytochrome P450 3A4. J Biol Chem 282:26865-26873.
13. Denisov IG and Sligar SG (2011) Cytochromes P450 in nanodiscs. Biochim Biophys Acta 1814:223-229.
14. Falck JR, Belosludtsev YY, Reddy KK, Reddy KM, Shortt MF, Chauhan K, Capdevila JH, and Wei SZ (1997) Eicosanoid biosynthesis: differential inhibition of cytochrome P450 epoxygenase and omega-hydroxylase. Bioorg Med Chem Lett 7:3053-3056.
15. Grinkova YV, Denisov IG, and Sligar SG (2010) Functional reconstitution of monomeric CYP3A4 with multiple cytochrome P450 reductase molecules in nanodiscs. Biochem Biophys Res Commun 398:194-198.
16. Guengerich FP (1987) Oxidative cleavage of carboxylic esters by cytochrome P-450. J Biol Chem 262:8459-8462.
17. Huang W, Jiang D, Wang X, Wang K, Sims CE, Allbritton NL, and Zhang Q (2011) Kinetic analysis of PI3K reactions with fluorescent PIP2 derivatives. Anal Bioanal Chem 401:1881-1888.
18. Imig JD and Hammock BD (2009) Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 8:794-805.
19. Kogan NM and Mechoulam R (2007) Cannabinoids in health and disease. Dialogues Clin Neurosci 9:413-430.
20. Lafite P, André F, Zeldin DC, Dansette PM, and Mansuy D (2007) Unusual regioselectivity and active site topology of human cytochrome P450 2J2. Biochemistry 46:10237-10247.
21. Loughran PA, Roman LJ, Miller RT, and Masters BS (2001) The kinetic and spectral characterization of the E. coli-expressed mammalian CYP4A7: cytochrome b5 effects vary with substrate. Arch Biochem Biophys 385:311-321.
22. McDougle DR, Palaria A, Magnetta E, Meling DD, and Das A (2013) Functional studies of N-terminally modified CYP2J2 epoxygenase in model lipid bilayers. Protein Sci 22:964-979.
23. Mukhopadhyay P, Mohanraj R, Bátkai S, and Pacher P (2008) CB1 cannabinoid receptor inhibition: promising approach for heart failure? Congest Heart Fail 14:330-334.
24. Nath A, Grinkova YV, Sligar SG, and Atkins WM (2007) Ligand binding to cytochrome P450 3A4 in phospholipid bilayer nanodiscs: the effect of model membranes. J Biol Chem 282:28309-28320.
25. Orlando BJ, McDougle DR, Lucido MJ, Eng ET, Graham LA, Schneider C, Stokes DL, Das A, and Malkowski MG (2014) Cyclooxygenase-2 catalysis and inhibition in lipid bilayer nanodiscs. Arch Biochem Biophys 546:33-40.
26. Pacher P, Bátkai S, and Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389-462.
27. Pacher P and Steffens S (2009) The emerging role of the endocannabinoid system in cardiovascular disease. Semin Immunopathol 31:63-77.
28. Panigrahy D, Edin ML, Lee CR, Huang S, Bielenberg DR, Butterfield CE, Barnés CM, Mammoto A, Mammoto T, and Luria A,, et al. (2012) Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest 122:178-191.
29. Peng HM, Raner GM, Vaz AD, and Coon MJ (1995) Oxidative cleavage of esters and amides to carbonyl products by cytochrome P450. Arch Biochem Biophys 318:333-339.
30. Pretorius PJ, Pohl WG, Smithen CS, and Inesi G (1969) Structural and functional characterization of dog heart microsomes. Circ Res 25:487-499.
31. Rouzer CA and Marnett LJ (2011) Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem Rev 111:5899-5921.
32. Snider NT, Kornilov AM, Kent UM, and Hollenberg PF (2007) Anandamide metabolism by human liver and kidney microsomal cytochrome p450 enzymes to form hydroxyeicosatetraenoic and epoxyeicosatrienoic acid ethanolamides. J Pharmacol Exp Ther 321:590-597.
33. Snider NT, Nast JA, Tesmer LA, and Hollenberg PF (2009) A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist. Mol Pharmacol 75:965-972.
34. Snider NT, Sikora MJ, Sridar C, Feuerstein TJ, Rae JM, and Hollenberg PF (2008) The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6. J Pharmacol Exp Ther 327:538-545.
35. Snider NT, Walker VJ, and Hollenberg PF (2010) Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications. Pharmacol Rev 62:136-154.
36. Spector AA (2009) Arachidonic acid cytochrome P450 epoxygenase pathway. J Lipid Res 50:S52-S56.
37. Sridar C, Snider NT, and Hollenberg PF (2011) Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6. Drug Metab Dispos 39:782-788.
38. Stark K, Dostalek M, and Guengerich FP (2008) Expression and purification of orphan cytochrome P450 4X1 and oxidation of anandamide. FEBS J 275:3706-3717.
39. Westphal C, Konkel A, and Schunck WH (2011) CYP-eicosanoids - a new link between omega-3 fatty acids and cardiac disease? Prostaglandins Other Lipid Mediat 96:99-108.
40. Wu S, Moomaw CR, Tomer KB, Falck JR, and Zeldin DC (1996) Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271:3460-3468.
41. Yang J, Dong H, and Hammock BD (2011) Profiling the regulatory lipids: another systemic way to unveil the biological mystery. Curr Opin Lipidol 22:197-203.
42. Zelasko S, Palaria A, and Das A (2013) Optimizations to achieve high-level expression of cytochrome P450 proteins using Escherichia coli expression systems. Protein Expr Purif 92:77-87.
43. Zeldin DC, Foley J, Goldsworthy SM, Cook ME, Boyle JE, Ma J, Moomaw CR, Tomer KB, Steenbergen C, and Wu S (1997) CYP2J subfamily cytochrome P450s in the gastrointestinal tract: expression, localization, and potential functional significance. Mol Pharmacol 51:931-943.
44. Zhu Y, Schieber EB, McGiff JC, and Balazy M (1995) Identification of arachidonate P-450 metabolites in human platelet phospholipids. Hypertension 25:854-859.